JPMorgan has launched a healthcare venture capital team targeting the life sciences.
The team, Life Sciences Private Capital, plans to invest in early- to later-stage healthcare companies and seeks to capitalize on innovation in areas such as genetic medicine, autoimmune diseases, cardiometabolic diseases and rare disorders, according to a Nov. 1 press release from JPMorgan.
A group of advisers will assist the investment team, meeting regularly and providing guidance as needed to help portfolio companies. The advisers are:
- Laurie Glimcher, MD, president and CEO of the Boston-based Dana-Farber Cancer Institute
- Jeffrey Leiden, MD, PhD, executive chair and former CEO of drug developer Vertex Pharmaceuticals
- Frederic Moll, MD, a robotic surgery pioneer and entrepreneur who is now an executive at Johnson & Johnson
- Stephen Oesterle, MD, former senior vice president for medicine and technology at medical-technology company Medtronic
- Robert Stockman, co-founder and former CEO of medical device company REVA Medical